The decade of vaccine

12 May 2015 18:00 – 18:00
Location: VUB, campus Etterbeek, Pleinlaan 2, Elsene, Brussel, België
Category: Young
Ticket Type Price Quantity
Standard Ticket €4.00 N/A

Jong-KVCV and Solvay Kring would like to invite you to the evening lecture entitled 'the decade of vaccine'. The lecture is part of a series on closing the gap between business and science. During the lecture, scientific aspects of vaccines (research and development,...) will be discussed as well as the management aspects (production, distribution, commercialization, ...) that entrail such developments.

The lecture will take place on the 12th of May 2015, starting at 18h. Location of the lecture is room D0.03 on the Etterbeek campus. Admission is free of charge for members of Solvay Kring and KVCV, non-members pay a small fee of 4€. A reception will be held afterwards.

Speaker for this event will be Benjamin Hulot. He is a Chemical Engineer at the Global Industrial Operation department at GlaxoSmithKline, which deliver over two million vaccines safely, every day, to people in 90% of the world’s countries. Benjamin has more than 10 years of management experience in the vaccine industry, especially in antigen manufacturing. His team is currently preparing the launch for a new building in Wavre (Belgium) to ensure the supply of whooping cough vaccines. The decade of vaccine is a framework to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born and where they live.

GlaxoSmithKline is a world’s leading vaccine company, involved in vaccine research, development and production. They have 16 candidate vaccines in development and a broad portfolio of over 30 vaccines to prevent illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. Globally, more than 12,000 people are working together to deliver vaccines safely, every day, to people in 90% of the world’s countries. In 2013, GSK distributed around 860 million doses of vaccine, 80% of them to least developed, low and middle income countries.

Registration is not mandatory but strongly recommanded. Register for this lecture.

Search an event